Skip to content
  1. Home
  2. >Test Catalog
  3. >Pharmacogenomics
  4. >Pgx Fluoropyrimidines Dpyd Test
Back to catalog

Pharmacogenomics (PGx) Fluoropyrimidines DPYD Test

A targeted pharmacogenomic test evaluating the DPYD gene to predict fluoropyrimidine treatment efficacy and side effect risk, powered by the Helix Exome+® platform.

Turnaround

6-9 days

Turnaround Requery

≤ 5 minutes

Test Description

This test evaluates 1 gene associated with response to certain medications including fluoropyrimidines. Results from this test may help in predicting treatment efficacy and risk of side effects for these drugs.

View the complete description of this test
Sample report

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Indications for Testing

Patients in whom fluoropyrimidines are being considered, have been ineffective, or caused side effects.

Methodology

This test utilizes next-generation sequencing to determine star alleles and metabolizer status for DPYD.

Technical Specifications

Reportable rangeDPYD: *1, *2A, *3, *4, *6-*8, *9B, *10-*13, HapB3, rs150036960, rs72549310, rs80081766, rs150385342, rs141462178, rs200562975, rs2297595, rs139834141, rs6670886, rs115232898, rs72549308, rs72549307, r...

Genes Tested

DPYD

Showing 1 of 1 genes in this panel

Other Tests to Consider

Test

Malignant Hyperthermia Susceptibility Panel

3

genes

Test

Pharmacogenomics (PGx) APOE Test

1

gene

Test

Pharmacogenomics (PGx) Level A Panel

16

genes

Test

Pharmacogenomics (PGx) Pain Panel

7

genes

Important Test Information

Turnaround time: Typically 7-10 days (standard), Typically < 5 minutes (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

Cancer and other conditions

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.